PHAR (PHAR) Stock Price & Analysis
PHAR (PHAR) fell 4.61% to USD 10.97 as of September 9, 2026 at 22:07 UTC, according to Nexqual real-time market data.
PHAR last closed at USD 11.5; the session ranged USD 10.97–11.54 on volume of 11,903 shares. Market capitalization is $776.44M, with a 52-week range of USD 9.62–21.34 (NGM). Source: Nexqual, September 9, 2026 at 22:07 UTC.
Key Statistics (as of September 9, 2026 at 22:07 UTC)
| Price | USD 10.97 |
|---|---|
| Change | ▼ 4.61% (down) |
| Previous Close | USD 11.5 |
| Open | USD 11.15 |
| Day Range | USD 10.97 – 11.54 |
| 52-Week Range | USD 9.62 – 21.34 |
| Volume | 11,903 shares |
| Market Cap | $776.44M |
| Exchange | NGM |
Technical Analysis (PHAR)
Nexqual's technical model rates PHAR "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of September 9, 2026 at 22:07 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 38.76 (neutral) |
| vs SMA50 | Below (USD 12.24) |
| MACD | -0.22 (negative) |
Analyst Ratings (PHAR)
Wall Street analysts rate PHAR "None" based on 4 analysts, with a mean price target of USD 34.35 (range USD 23.4–39), per Nexqual as of September 9, 2026 at 22:07 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 34.35 |
| High Target | USD 39 |
| Low Target | USD 23.4 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (PHAR)
| EPS Estimate | USD 0.2 |
|---|---|
| Revenue Estimate | $104.07M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0 vs est 0.06 ▼ miss |
| 2026-03-31 | USD -0.07 vs est 0 ▼ miss |
| 2025-12-31 | USD 0.07 vs est 0.01 ▲ beat |
| 2025-09-30 | USD 0.01 vs est 0 ▲ beat |
Source: Nexqual, September 9, 2026 at 22:07 UTC.
Financials & Fundamentals (PHAR)
| Total Revenue | $366.48M |
|---|---|
| Revenue Growth (YoY) | -3.20% |
| Gross Margin | +86.52% |
| Operating Margin | +1.46% |
| Profit Margin | +2.54% |
| ROE | +3.65% |
| Debt / Equity | 41.89 |
| Current Ratio | 3.01 |
| Total Cash | $158.28M |
| Total Debt | $113.30M |
| Free Cash Flow | $37.69M |
Source: Nexqual, September 9, 2026 at 22:07 UTC.
Financial Health Score (PHAR)
Nexqual rates PHAR's overall financial health "Solid" across five dimensions, as of September 9, 2026 at 22:07 UTC.
| Growth | Strong — Revenue +27% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 87%, operating 1% |
| Balance Sheet | Strong — $158M cash vs $113M debt, net cash position |
| Cash Flow | Solid — FCF $38M, 10% margin |
| Efficiency | Weak — ROE 4%, ROA 3.5% |
Ownership (PHAR)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.14% |
| Shares Outstanding | 70.78M |
| Float | 69.66M |
| Short % of Float | +0.10% |
Source: Nexqual, September 9, 2026 at 22:07 UTC.
Leadership (PHAR)
PHAR is led by Fabrice Chouraqui M.B.A., Ph.D., Pharm.D., CEO & Executive Director, per Nexqual as of September 9, 2026 at 22:07 UTC.
| CEO & Executive Director | Fabrice Chouraqui M.B.A., Ph.D., Pharm.D. |
|---|---|
| Chief Financial Officer | Kenneth Lynard EMBA, M.Sc. (age 57) |
| Medical Director | Magnus Hansson (age 49) |
Major Backers & Investors (PHAR)
Notable institutional backers of PHAR include Mac Alpha Capital Management, LP, according to Nexqual as of September 9, 2026 at 22:07 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Mac Alpha Capital Management, LP | 3.04% |
Source: Nexqual, September 9, 2026 at 22:07 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PHVS | Pharvaris N.V. | USD 37.74 | ▲ 7.06% |
| NBTX | Nanobiotix S.A. | USD 36.64 | ▼ 5.57% |
| PRTCY | PureTech Health PLC | USD 16.55 | ▲ 0% |
| IVA | Inventiva S.A. - American Depos | USD 4.45 | ▼ 6.9% |
| SLN | Silence Therapeutics Plc - Amer | USD 13.55 | ▼ 7.13% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 22:07 UTC. This page is informational and not investment advice.